Novo Nordisk reports the result for its experimental next-generation drug in women with obesity or overweight, based on newly analyzed trial data.
Recap by typeshit. Full story at Reuters on MSN.
A new GLP-1 described as stronger than current options is being tested in trials, and researchers lay out what people should understand about it.
A SURPASS-4 analysis at ASN Kidney Week 2026 found rapid kidney decline in 5% on tirzepatide versus 13% on insulin glargine, with the biggest gains in high protein groups.
Among 208,970 matched adults with type 2 diabetes, GLP-1 starters had 0.15% new diagnoses versus 0.10% on DPP-4 drugs. Authors call it a signal needing confirmation.
Researchers used AI to identify fungal peptides that taste salty or boost saltiness, aimed at cutting sodium in food. A food science find rather than a drug story.
Bloomberg says the boom in GLP-1 use has opened a risky trade in weight loss drugs brought into Brazil illegally.
Covers how the two drugs differ, why compounders face limits now that shortages are over, and Tennessee warnings about counterfeit shots sold online.
Loading…